POLATUZUMAB VEDOTIN-PIIQ for Diffuse large b-cell lymphoma refractory: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 158 adverse event reports in the FDA FAERS database where POLATUZUMAB VEDOTIN-PIIQ was used for Diffuse large b-cell lymphoma refractory.
Most Reported Side Effects for POLATUZUMAB VEDOTIN-PIIQ
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 753 | 23.7% | 207 | 36 |
| Off label use | 484 | 15.2% | 112 | 47 |
| Death | 367 | 11.5% | 367 | 23 |
| Covid-19 | 202 | 6.4% | 66 | 50 |
| Neutropenia | 160 | 5.0% | 44 | 25 |
| Pyrexia | 119 | 3.7% | 34 | 38 |
| Drug ineffective | 118 | 3.7% | 44 | 10 |
| No adverse event | 109 | 3.4% | 1 | 0 |
| Blood lactate dehydrogenase increased | 108 | 3.4% | 29 | 10 |
| Febrile neutropenia | 107 | 3.4% | 26 | 41 |
| Platelet count decreased | 103 | 3.2% | 29 | 36 |
| Diarrhoea | 95 | 3.0% | 28 | 23 |
| Lymphoma | 91 | 2.9% | 10 | 5 |
| Neutrophil count decreased | 90 | 2.8% | 12 | 27 |
| Neuropathy peripheral | 87 | 2.7% | 4 | 8 |
Other Indications for POLATUZUMAB VEDOTIN-PIIQ
Diffuse large b-cell lymphoma (2,228)
Product used for unknown indication (395)
Diffuse large b-cell lymphoma recurrent (107)
Non-hodgkin's lymphoma (57)
B-cell lymphoma (51)
Follicular lymphoma (32)
Lymphoma (32)
Diffuse large b-cell lymphoma stage iv (22)
Richter's syndrome (15)
Diffuse large b-cell lymphoma stage iii (14)
Other Drugs Used for Diffuse large b-cell lymphoma refractory
RITUXIMAB (667)
EPCORITAMAB-BYSP (353)
AXICABTAGENE CILOLEUCEL (336)
BENDAMUSTINE (283)
CYCLOPHOSPHAMIDE (226)
POLATUZUMAB VEDOTIN (223)
ETOPOSIDE (165)
GEMCITABINE (147)
LENALIDOMIDE (143)
DEXAMETHASONE (136)